Piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams

Assignee: Pfizer Inc

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,101,885
App. No.: 10/868,055
Granted: Sep 5, 2006
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention relates to compounds of formula I wherein Ar, Y and G are as defined in the specification, a is 1 to 4, Z and W are carbon or nitrogen and n is 1, 2 or 3; and to pharmaceutical compositions comprising the compound of formula I and a pharmaceutically effective carrier; and to a method useful in treating or preventing in mammals, including humans, a disorder or condition selected from the group consisting of anxiety, depression, dysthymia, major depressive disorder, migraine, post-traumatic stress disorder, avoidant personality disorder, borderline personality disorder and phobias.

Claims (61)

1. A compound of the formula I

wherein Ar is selected from phenyl or pyridyl;

wherein phenyl may be optionally substituted with one substituent selected from halogen, trifluoromethyl, pyridyl, oxazoyl, pyrazolyl, isoxazolyl, 2-oxo-piperidinyl, 2-oxo-oxazolidin-3-yl, and 2-oxo-pyrrolidin-1-yl;

Y is hydrogen;

wherein R 1 is C 1 –C 8 alkyl, or C 1 –C 8 alkoxy;

G is (C 1 –C 6 )alkyl, wherein said alkyl is straight-chained, branched or cyclic, and said (C 1 –C 6 ) alkyl is optionally substituted with OH, or OR′, wherein R′ is straight-chained, branched or cyclic (C 1 –C 6 )alkyl;

a is 1;

Z is independently carbon or nitrogen;

W is carbon;

n is 1, 2 or 3; and

the pharmaceutically acceptable salts thereof.

2. A compound according to claim 1 wherein Ar is phenyl having a para substituent selected from bromine, trifluoromethyl, 2-oxo-oxazolidin-3-yl or 2-oxo-pyrrolidin-1-yl.

3. A compound selected from:

1-(4-Bromo-phenyl)-3-[2-(4-methyl-piperazin-1-yl)-pyridin-3-yloxy]-pyrrolidin-2-one;

3-[2-(4-Methyl-piperazin-1-yl)-phenoxy]-1-(4-trifluoromethyl-phenyl)-pyrrolidin-2-one;

3-[2-(4-Methyl-piperazin-1-yl)-phenoxy]-1-(4-bromo-phenyl)-pyrrolidin-2-one;

3-[2-(4-Methyl-piperazin-1-yl)-phenoxy]-1-(4-(2-oxo-pyrrolidin-1-yl)-phenyl)-pyrrolidin-2-one;

3-[2-(4-Methyl-piperazin-1-yl)-phenoxy]-1-[4-bromo-phenyl]-piperidin-2-one;

3-[2-(4-Methyl-piperazin-1-yl)-phenoxy]-1-[4-(2-oxo-pyrrolidin-1-yl)-phenyl]-piperidin-2-one;

3-[2-(4-Methyl-piperazin-1-yl)-phenoxy]-1-[4-(2-oxo-oxazolidin-3-yl)-phenyl]-piperidin-2-one;

3-[2-(4-Methyl-piperazin-1-yl)-phenoxy]-1-(4-trifluoromethyl-phenyl)-piperidin-2-one;

1-(4-Trifluoromethyl-phenyl)-3-[2-(4-methyl-piperazin-1-yl)-pyridin-3-yloxy]-pyrrolidin-2-one;

1-(4-tert-Butyl-phenyl)-3-[2-(4-methyl-piperazin-1-yl)-pyridin-3-yloxy]-pyrrolidin-2-one;

1-[4-(2-tert-Butyl-oxazol-4-yl)-phenyl]-3-[2-(4-methyl-piperazin-1-yl)-pyridin-3-yloxy]-pyrrolidin-2-one;

1-(4-{3-[2-(4-Methyl-piperazin-1-yl)-pyridin-3-yloxy]-2-oxo-pyrrolidin-1-yl}-phenyl)-piperidin-2-one;

1-(4-{3-[2-(4-Methyl-piperazin-1-yl)-pyridin-3-yloxy]-2-oxo-pyrrolidin-1-yl}-phenyl)-pyrrolidinone;

1-[4-(3-pyridyl]-3-[2-(4-methyl-piperazin-1-yl)-pyridin-3-yloxy]-pyrrolidin-2-one;

1-[4-(4-pyridyl)-phenyl]-3-[2-(4-methyl-piperazin-1-yl)-pyridin-3-yloxy]-pyrrolidin-2-one;

1-[4-(Isopropoxy)-phenyl]-3-[2-(4-methyl-piperazin-1-yl)-pyridin-3-yloxy]-pyrrolidin-2-one;

1-[4-(Trifluoromethoxy)-phenyl]-3-[2-(4-methyl-piperazin-1-yl)-pyridin-3-yloxy]-pyrrolidin-2-one;

3-[2-(4-Methyl-piperazin-1-yl)-pyridin-3-yloxy]-1-[4-(tetrahydro-pyran-4-yl)-phenyl]-pyrrolidin-2-one;

1-[4-(2-Oxazolyl)-phenyl]-3-[2-(4-methyl-piperazin-1-yl)-pyridin-3-yloxy]-pyrrolidin-2-one;

1-[4-(1-Pyazolyl)-phenyl]-3-[2-(4-methyl-piperazin-1-yl)-pyridin-3-yloxy]-pyrrolidin-2-one;

1-[(4-(2-Methyl)oxazolyl)-phenyl]-3-[2-(4-methyl-piperazin-1-yl)-pyridin-3-yloxy]-pyrrolidin-2-one;

1-[4-(3-Isoxazolyl)-phenyl]-3-[2-(4-methyl-piperazin-1-yl)-pyridin-3-yloxy]-pyrrolidin-2-one; and

1-[(2-(5-Methyl)oxazolyl)-phenyl]-3-[2-(4-methyl-piperazin-1-yl)-pyridin-3-yloxy]-pyrrolidin-2-one or a pharmaceutically acceptable salt thereof.

4. A method of treating a disorder or condition in a mammal selected from the group consisting of anxiety, depression, dysthymia, major depressive disorder, migraine, post-traumatic stress disorder, avoidant personality disorder, borderline personality disorder and phobias, comprising administering to a mammal in need of such treatment an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.

5. A method of treating a disorder or condition in a mammal selected from the group consisting of anxiety, depression, dysthymia, major depressive disorder, migraine, post-traumatic stress disorder, avoidant personality disorder, borderline personality disorder and phobias, comprising administering to a mammal in need of such treatment an effective amount of a compound wherein said compound is selected from: